Australia markets open in 7 hours 14 minutes

  • ALL ORDS

    7,111.40
    +32.50 (+0.46%)
     

  • AUD/USD

    0.7753
    +0.0040 (+0.52%)
     

  • ASX 200

    6,824.70
    +24.30 (+0.36%)
     

  • OIL

    52.70
    -0.07 (-0.13%)
     

  • GOLD

    1,853.50
    -1.70 (-0.09%)
     

  • BTC-AUD

    41,084.92
    -871.46 (-2.08%)
     

  • CMC Crypto 200

    639.99
    -7.33 (-1.13%)
     
Sign up NOW ✉️:

Want to master your money in 2021?

Join Yahoo Finance's 6-week bootcamp challenge!

CFP sucks, ACC & SEC title game preview, National Signing Day

Pete Thamel and Dan Wetzel
·1-min read

Subscribe to The Yahoo Sports College Podcast
Apple Podcasts • Stitcher • Google Podcasts • Spotify

The College Football Playoff Committee has really done it this time. Dan Wetzel, Pete Thamel and SI’s Pat Forde eviscerate the latest abomination from Gary Barta and company. What were they thinking with the likes of Florida, Iowa State and Coastal Carolina?

The guys eventually calm down to preview the two massive title tilts this weekend as Clemson and Notre Dame square off for ACC supremacy while Alabama and Florida clash for the SEC title belt. Will Trevor Lawrence be the difference this round against the Irish?

Early National Signing Day came and went without the usual flair. The guys take a step back and look at the future of the recruiting circus before highlighting a few classes including LSU, USC and Ole Miss.

The guys then pick their final games against the spread to wrap up the season-long Race for the Case! The entire podcast crew is above .500 and still in the hunt for the title...

Check out the rest of the Yahoo Sports Podcast family at https://apple.co/2Abi8jk or at yahoosports.com/podcasts

Latest stories

  • Outlook on the Non-woven Tape Global Market to 2025 - Growing Demand for Medical and Hygienic Purposes - ResearchAndMarkets.com

    The "Non-woven Tape Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

  • Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors

    STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the appointments of Elizabeth Yeu, M.D., Partner, Virginia Eye Consultants, and K. Peony Yu, M.D., retired Chief Medical Officer, FibroGen Inc., to its Board of Directors, effective January 21, 2021.

  • Insights on the Hot-Rolled Round Bars of Stainless Steel Global Market to 2025 - ResearchAndMarkets.com

    The "World - Hot-Rolled Round Bars Of Stainless Steel - Market Analysis, Forecast, Size, Trends and Insights" report has been added to ResearchAndMarkets.com's offering.

  • Global Cybersecurity Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

    The "Cybersecurity Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

  • CEE MARKETS-Crown hits 5-month high, forint extends losses

    Hungary's forint led losses, dropping 0.3% on the day to 358.60 to the euro, extending losses after the central bank held steady on interest rates but said it would ramp up bond purchases to shore up the pandemic-hit economy. Hungary's central bank, like others in the region, has added support to markets since last year, depressing yields. The Czech central bank has refrained from bond purchases, unlike peers, and it has struck a more hawkish tone on policy in recent months.

  • Today only: Take an extra 20% off sale items at Athleta

    Enter code EXTRA20 at checkout to take an extra 20% off all sale and clearance items Tuesday only.

  • ‘Bridgerton’ fans have spotted some modern mistakes in the first episode

    Eagled-eyed Bridgerton fans have spotted an overlooked detail in the series’ first episode that doesn’t make sense given the show’s 19th century setting. The first episode of the Shonda Rhimes series introduces us to Julia Quinn’s Regency-era England circa 1813. During the opening scene of the show, horse-drawn carriages take the main characters down a cobblestone road — but while cobblestone roads and carriages were common in the 1800s, this particular road featured a yellow traffic line.

  • Sony's A1 is a $6,500 50MP camera that shoots 30fps bursts and 8K video

    Sony has just dropped a bomb on the camera world with the launch of the A1, its new flagship full-frame mirrorless camera with some breakthrough features

  • What Leon Black Got for Paying Jeffrey Epstein $158 Million

    (Bloomberg) -- Leon Black viewed Jeffrey Epstein as a “confirmed bachelor with eclectic tastes, who often employed attractive women.”The private equity titan was willing to overlook that Epstein had served 13 months in a Florida jail after soliciting an underage prostitute. That was partly because Epstein claimed the girl had lied about her age, while Black, co-founder of Apollo Global Management Inc., believed in second chances, particularly for his well-connected friend.Thus continued a relationship between the men that was laid out in a report released Monday by law firm Dechert, commissioned by Apollo’s board after news stories about their financial ties. The investigation found that Black paid Epstein $158 million between 2012 and 2017 -- after the sex offender pleaded guilty to felony charges in 2008 -- for advisory services that helped expand the wealth of one of America’s richest men.The report made clear that Apollo never retained Epstein for any services and that he never invested in any Apollo-managed funds. Dechert found no evidence that Black, 69, was involved in any way of Epstein’s criminal activities, and the billionaire maintains he had no knowledge of Epstein’s abuse of underage girls. Still, the findings showed how the disgraced adviser’s knowledge of the tax system and skill managing the affairs of the ultra-rich helped Black save at least $1 billion, and potentially more than $2 billion.At the same time Apollo revealed details of the report, the company said Black would step down as chief executive officer. He’ll remain chairman.Tax SavingsThe Dechert report details a friendship going back to the 1990s, with Black impressed by Epstein’s ties to prominent figures in business, politics and science, including researchers at Harvard University and the Massachusetts Institute of Technology. Black was a frequent visitor to Epstein’s Manhattan mansion, confided personal matters to him and visited his homes around the globe.Dechert also laid out the ways Epstein was useful to Black, who’s worth almost $10 billion, according to the Bloomberg Billionaires Index.The business arrangement started in 2012, according to the law firm, which reviewed over 60,000 documents.Black a few years earlier had set up a Grantor Retained Annuity Trust, or GRAT. These vehicles, which are popular with extremely wealthy Americans, are structured so that appreciation in assets placed in a GRAT can go to heirs without paying U.S. estate and gift taxes. But Black’s had a flaw and there was a risk of a tax assessment of $500 million, which could rise to $1 billion or more if it wasn’t resolved.Epstein offered what the report described as a “unique solution.” It was the first project Epstein worked on for Black and possibly the most valuable.In 2015, Epstein helped with another transaction designed to save Black’s children on taxes, known as a step-up basis transaction. The complicated arrangement, which took nine months to execute, involved loans between Black and trusts, and avoiding capital gains taxes for his beneficiaries. Epstein claimed the move saved $600 million.Yachts, PlaneEpstein, a Brooklyn native, was an enigma to many inside and outside of finance. He attended Cooper Union and New York University’s Courant Institute of Mathematical Sciences but left both without a degree. He briefly had a job at Bear Stearns Cos. and before his first arrest worked extensively for lingerie mogul Les Wexner. The L Brands founder severed ties with Epstein after his first conviction and later accused him of misappropriating “vast sums of money from me and my family.” But Epstein had helped Wexner with his finances and purchases such as real estate.He did many of those same things for Black.Epstein helped respond to audits, and advised on how to manage Black’s art, yacht and airplane, according to the Dechert report.“Epstein would get into the weeds on obscure issues about which otherwise highly competent Family Office employees were not knowledgeable,” the report said.One of Epstein’s contributions, according to the report, was convincing Black to focus on these issues, as well as meeting with his family and explaining how the estate was organized. He would prepare detailed “fire drill” plans, testing how Black’s estate would be taxed under different scenarios.‘Caustic Force’Black’s full-time staff didn’t always appreciate Epstein’s contributions. He was “generally a disruptive and caustic force within the family office,” the report said, one who “had a habit of overdramatizing even minor perceived errors.”Epstein would take credit for others’ ideas, while compiling long lists of his own suggestions. Many of his creative estate-planning schemes didn’t hold up under scrutiny. According to witnesses, including Black, “part of the challenge of working with Epstein was separating the good ideas from the bad ones.”“What’s bizarre to me is having Epstein in any way in charge of your estate planning,” said University of Richmond law professor Allison Tait. “He didn’t just leave this to his family office staff, who were likely highly competent.”But the payments racked up. Black paid Epstein $50 million in 2013, $70 million in 2014 and $30 million the following year. He made a $10 million donation to Gratitude America in October 2015, which was a charitable organization affiliated with Epstein.That sort of compensation is unusual. Estate planning attorneys and tax advisers are typically paid by the hour or by the transaction. IRS regulations forbid tax practitioners from charging contingent fees “in connection with any matter before the Internal Revenue Service.”But Epstein, with his atypical role and background, could avoid those rules, said Jay Soled, a Rutgers University professor who is also a practicing estate tax attorney. “This is a very unusual arrangement because he doesn’t really have training.”Beginning in 2016, “Black and Epstein’s professional and personal relationship deteriorated,” according to the report. One dispute was over a payment tied to the step-up transaction, with Black refusing to pay Epstein tens of millions of dollars that Epstein believed he had earned.Epstein pushed back on the issue through emails that invoked his friendship with the billionaire and referenced personal matters shared in confidence. Black held firm and at an April 2018 meeting it was determined that while Epstein had played a key role in the deal, the idea came from one of Black’s external lawyers.Black also thought that the amounts he was paying Epstein would be fully deductible on his tax returns -- because this is what Epstein told him -- and this wasn’t the case.Black’s last payment to Epstein was made in April 2017, and in 2018, Epstein repaid a portion of two loans that were outstanding to Black but never repaid the balance, according to the report. Black and Epstein stopped communicating in 2018, the year before Epstein was arrested on charges of sex trafficking minors and later died in jail. His death was ruled a suicide.(Updates with external comment in 19th paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Britain pins global cooperation hopes on shared climate fears

    Shared concern over climate change could help strengthen global cooperation more broadly in the run-up to a U.N. climate summit in November, its British president Alok Sharma said on Tuesday. With the world struggling to cut planet-warming emissions fast enough to avoid catastrophic warming, diplomats fear that tensions in areas from U.S.-China trade to debt relief for developing countries could hinder progress at the talks. "2021 is absolutely going to be a critical year for climate," Sharma told a virtual meeting of the World Economic Forum.

  • Report: Jake Paul will fight Ben Askren in eight-round boxing match April 17

    Jake Paul is going to take on a professional fighter in April.

  • INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Encore Capital Group, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ECPG

    INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Encore Capital Group, Inc.’s Directors and Officers for Breach of Fiduciary Duties–ECPG

  • Distilled Spirits Council of the United States Launches DISCUS Academy

    Distilled Spirits Council announces launch of DISCUS Academy an initiative to provide education/training for distilled spirits industry professionals.

  • Global Motorcycle Engine Management Systems Industry

    Global Motorcycle Engine Management Systems Market to Reach US$32. 6 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for Motorcycle Engine Management Systems estimated at US$12.New York, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Motorcycle Engine Management Systems Industry" - https://www.reportlinker.com/p05957446/?utm_source=GNW 6 Billion in the year 2020, is projected to reach a revised size of US$32.6 Billion by 2027, growing at a CAGR of 14.6% over the analysis period 2020-2027.Commuter, one of the segments analyzed in the report, is projected to grow at a 15.9% CAGR to reach US$17.7 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Mid-Premium segment is readjusted to a revised 15.1% CAGR for the next 7-year period. This segment currently accounts for a 30.7% share of the global Motorcycle Engine Management Systems market. The U.S. Accounts for Over 29.6% of Global Market Size in 2020, While China is Forecast to Grow at a 13.9% CAGR for the Period of 2020-2027 The Motorcycle Engine Management Systems market in the U.S. is estimated at US$3.7 Billion in the year 2020. The country currently accounts for a 29.58% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$5.6 Billion in the year 2027 trailing a CAGR of 13.9% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.1% and 12.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR while Rest of European market (as defined in the study) will reach US$5.6 Billion by the year 2027. Premium Segment Corners a 19.2% Share in 2020 In the global Premium segment, USA, Canada, Japan, China and Europe will drive the 9.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.9 Billion in the year 2020 will reach a projected size of US$3.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.9 Billion by the year 2027.We bring years of research experience to this 8th edition of our report. The 129-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, Bazzaz, Inc.BMW AGContinental AGDelphi Auto PartsDenso CorporationInfineon Technologies AGKawasaki Heavy Industries Ltd.Magneti Marelli SpAMcLaren Applied TechnologiesMitsubishi Electric CorporationNiki Auto Motor Ltd.NXP Semiconductors NVOmnitek Engineering, Corp.Robert Bosch GmbHWalbro LLC Read the full report: https://www.reportlinker.com/p05957446/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Motorcycle Engine Management Systems Competitor Market Share Scenario Worldwide (in %): 2018E 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Motorcycle Engine Management Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 2: World Historic Review for Motorcycle Engine Management Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 3: World 15-Year Perspective for Motorcycle Engine Management Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027 Table 4: World Current & Future Analysis for Commuter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 5: World Historic Review for Commuter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 6: World 15-Year Perspective for Commuter by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 7: World Current & Future Analysis for Mid-Premium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 8: World Historic Review for Mid-Premium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 9: World 15-Year Perspective for Mid-Premium by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 10: World Current & Future Analysis for Premium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 11: World Historic Review for Premium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 12: World 15-Year Perspective for Premium by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Motorcycle Engine Management Systems Market Share (in %) by Company: 2018 & 2027 Market Analytics Table 13: USA Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 14: USA Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 15: USA 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 CANADA Table 16: Canada Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 17: Canada Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 18: Canada 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 JAPAN Table 19: Japan Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 20: Japan Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 21: Japan 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 CHINA Table 22: China Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 23: China Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 24: China 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 EUROPE Market Facts & Figures European Motorcycle Engine Management Systems Market: Competitor Market Share Scenario (in %) for 2018 & 2027 Market Analytics Table 25: Europe Current & Future Analysis for Motorcycle Engine Management Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2018 through 2027 Table 26: Europe Historic Review for Motorcycle Engine Management Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 27: Europe 15-Year Perspective for Motorcycle Engine Management Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027 Table 28: Europe Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 29: Europe Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 30: Europe 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 FRANCE Table 31: France Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 32: France Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 33: France 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 GERMANY Table 34: Germany Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 35: Germany Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 36: Germany 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 ITALY Table 37: Italy Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 38: Italy Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 39: Italy 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 UNITED KINGDOM Table 40: UK Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 41: UK Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 42: UK 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 REST OF EUROPE Table 43: Rest of Europe Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 44: Rest of Europe Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 45: Rest of Europe 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 ASIA-PACIFIC Table 46: Asia-Pacific Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 47: Asia-Pacific Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 48: Asia-Pacific 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 REST OF WORLD Table 49: Rest of World Current & Future Analysis for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027 Table 50: Rest of World Historic Review for Motorcycle Engine Management Systems by End-Use - Commuter, Mid-Premium and Premium Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017 Table 51: Rest of World 15-Year Perspective for Motorcycle Engine Management Systems by End-Use - Percentage Breakdown of Value Sales for Commuter, Mid-Premium and Premium for the Years 2012, 2018 & 2027 IV. COMPETITION Total Companies Profiled: 35Read the full report: https://www.reportlinker.com/p05957446/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Guess ?, Inc.’s Directors and Officers for Breach of Fiduciary Duties – GES

    INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Guess ?, Inc.’s Directors and Officers for Breach of Fiduciary Duties – GES

  • Worldwide Iron or Non-Alloy Steel Angles, Shapes and Sections Industry to 2025 - Profiles of Major Producers - ResearchAndMarkets.com

    The "World - Angles, Shapes And Sections (Of Iron Or Non-Alloy Steel) - Market Analysis, Forecast, Size, Trends and Insights" report has been added to ResearchAndMarkets.com's offering.

  • Consumer Confidence in U.S. Improves on Outlook for Economy

    (Bloomberg) -- U.S. consumer confidence rose in January as Americans grew more upbeat about the outlook for the economy and job market in light of further fiscal aid and the distribution of coronavirus vaccines.The Conference Board’s index of sentiment increased to 89.3 from a revised 87.1 reading in December, according to a report on Tuesday. The median forecast in a Bloomberg survey of economists called for a reading of 89.The gauge of expectations rose to a three-month high of 92.5, while a measure of sentiment about current conditions decreased to 84.4, the worst reading since May.The overall improvement in sentiment follows last month’s passage of a $900 billion aid package and coincides with a proposed $1.9 trillion in additional stimulus. While the confidence index remains well below pre-pandemic levels as the health crisis prompts tighter restrictions on activity, a more widespread roll out of the vaccine and additional financial assistance could shore up sentiment.“Consumers’ appraisal of present-day conditions weakened further in January, with Covid-19 still the major suppressor,” Lynn Franco, senior director of economic indicators at the Conference Board, said in a statement. “Consumers’ expectations for the economy and jobs, however, advanced further, suggesting that consumers foresee conditions improving in the not-too-distant future.”The number of Americans that said jobs were currently hard to get increased to the highest level since May, underscoring a rocky labor market. The cutoff date for the preliminary results was Jan. 14.Still, the share of survey respondents who said better business conditions in the next six months increased to a three-month high of 33.7% from 29.5%. The share anticipating more jobs during that period climbed to 31.3%, also the highest since October.At the same time, a little more than two-thirds see their incomes remaining flat in the next six months, while the rest of respondents were about evenly split on whether their wages will rise or fall.Respondents indicated they were more likely to make big purchases in the months ahead. The share expecting to buy a new car increased to 10.7% from 9.8%, and more said they intended to buy a home.(Adds graphic)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent

    Trial met primary endpoint and key secondary endpoints with high statistical significanceResults from more than 1,000 high-risk patients were consistent with previous dataIn November, Lilly submitted a EUA request to the FDA for etesevimab and bamlanivimab together for mild to moderate COVID-19 in high-risk patients, which remains under review by the FDAFindings from BLAZE-4 trial provide data on lower doses of etesevimab and bamlanivimab together SHANGHAI, China, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that etesevimab (JS016 or LY-CoV016) 2800 mg and bamlanivimab (LY-CoV555) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, “events”) in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial, according to the company’s global partner Eli Lilly and Company (NYSE: LLY). Across 1,035 patients, there were 11 events (2.1 percent) in patients taking therapy and 36 events (7.0 percent) in patients taking placebo, representing a 70 percent risk reduction (p= 0.0004). There were 10 deaths total, all of which occurred in patients taking placebo, and no deaths in patients taking etesevimab and bamlanivimab together. Etesevimab and bamlanivimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. In the trial, the safety profile of etesevimab and bamlanivimab together was consistent with observations from other Phase 1, Phase 2 and Phase 3 trials evaluating these antibodies. Serious adverse events were reported at a similar frequency in the etesevimab and bamlanivimab together and placebo groups. Across multiple clinical trials, Lilly has collected safety and efficacy data in more than 4,000 participants treated with its neutralizing antibodies, either bamlanivimab alone or bamlanivimab and etesevimab together. Additionally, initial results from the ongoing BLAZE-4 trial provide viral load and pharmacodynamic/pharmacokinetic data which demonstrated lower doses, including etesevimab 1400 mg and bamlanivimab 700 mg together, are similar to etesevimab 2800 mg and bamlanivimab 2800 mg together. Lilly plans to explore even lower doses of etesevimab and bamlanivimab together, as lower doses can maximize available supply to treat more patients, allow potential for subcutaneous dosing, and potentially reduce the burden on healthcare system and patients through reduced infusion times. Bamlanivimab is authorized for emergency use by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients, and it has also been granted authorizations in several additional countries. In November, Lilly submitted a request to the FDA for emergency use authorization for etesevimab and bamlanivimab together as another treatment for mild to moderate COVID-19 in high-risk patients. It remains under review by the FDA. Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. As a result, Lilly is working with the FDA to potentially reduce infusion times to be as short as 16 minutes – a significant reduction from the currently authorized time of 60 minutes. This potential change is aimed at simplifying administration and reducing the burden on the healthcare system. Lilly will continue to accelerate the manufacturing of etesevimab in collaboration with Amgen, providing up to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021 – including more than 250,000 doses in the first quarter – for use around the world. About etesevimab（JS016）Etesevimab (JS016 or LY-CoV016) is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science (IMCAS). Junshi Biosciences leads development in Greater China, while Lilly leads development in the rest of the world. Lilly has successfully completed a Phase 1 study (NCT04441931) of etesevimab in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity. A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. Junshi Biosciences has completed a similar Phase 1 study in healthy volunteers in China and has initiated Phase 1b/2 trials in COVID-19 patients globally. About bamlanivimab（LY-CoV555）Bamlanivimab (LY-CoV555) is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19. Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients. About BLAZE-1BLAZE-1 (NCT04427501) is a randomized, double-blind, placebo-controlled Phase 2/3 study designed to assess the efficacy and safety of bamlanivimab alone or bamlanivimab and etesevimab together for the treatment of symptomatic COVID-19 in the outpatient setting. To be eligible, patients were required to have mild or moderate symptoms of COVID-19 as well as a positive SARS-CoV-2 test based on a sample collected no more than three days prior to drug infusion. In the Phase 2 portion of BLAZE-1, cohorts of mild to moderate recently diagnosed COVID-19 patients, were randomized to one of three doses of bamlanivimab (700 mg, 2800 mg, and 7000 mg), etesevimab 2800 mg plus bamlanivimab 2800 mg, or placebo. Results from the Phase 2 cohorts of BLAZE-1 were published in the New England Journal of Medicine and The Journal of the American Medical Association. In the Phase 3 portion of BLAZE-1, the combination therapy arms enrolled mild to moderate, recently diagnosed COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization, studying etesevimab 2800 mg plus bamlanivimab 2800 mg versus placebo. The primary outcome measure for the Phase 3 portion of the BLAZE-1 trial was the percentage of participants who experience COVID-related hospitalizations or death from any cause by day 29. The key secondary endpoints were change from baseline to day 7 in SARS-CoV-2 viral load, persistently high SARS-CoV-2 viral load on day 7, time to sustained symptom resolution, and COVID-related hospitalization, ER visit or death from any cause from baseline by day 29. Additional endpoints include change from baseline in viral load at other time points, symptom improvement, symptom resolution, as well as safety. The study is ongoing with additional treatment arms. Across all treatment arms, the trial will enroll up to 3,300 participants. About BLAZE-4BLAZE-4 (NCT04634409) is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of bamlanivimab alone, and bamlanivimab and etesevimab together, at various doses, versus placebo for the treatment of symptomatic COVID-19 in the outpatient setting. Across all treatment arms, the trial will enroll an estimated 1,000 participants in the United States and Puerto Rico. The primary outcome measure is percentage of participants who have a viral load greater than 5.27 at day 7. Additional endpoints include change from baseline to Day 7 in SARS-CoV-2 viral load, percentage of participants who experience COVID-related hospitalization, ER visit or death from baseline through Day 29, as well as safety. About Junshi BiosciencesFounded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016, China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com. About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/news.P-LLY Contact InformationIR Team:Junshi Biosciencesinfo@junshipharma.com+ 86 021-2250 0300 Solebury TroutBob Ai bai@soleburytrout.com+ 1 646.378-2926 PR Team:Junshi BiosciencesZhi Lizhi_li@junshipharma.com+ 86 021-6105 8800

  • Learn4Life Asks How Can We Help Students Regain Learning Lost During the Pandemic

    Educators and parents of all backgrounds are worried about learning losses suffered by their students during the pandemic. It has become clear that teachers can’t effectively serve 120+ high school students a day doing remote learning by trying to replicate the classroom experience through Zoom.

  • Oil Wavers With Concerns Lingering Over China Consumption

    (Bloomberg) -- Oil wavered as investors assess the potential for flagging Chinese demand against the expectation for shrinking global supplies.Futures in New York gave back most of their earlier gains after U.S. equity markets opened Tuesday. A coronavirus flare-up in China is threatening fuel demand during the Lunar New Year period, with the government encouraging millions not to travel to prevent the outbreak from spreading further. Still, exports of Russia’s Urals crude are expected to decline next month and Iraq’s production will also dip.Oil has surged almost 50% since the end of October but the rally has started to falter amid concerns about a sustained recovery in global fuel demand. Vaccine coverage won’t reach a point where it will stop the transmission of the virus in the foreseeable future, the World Health Organization said on Monday.Prices have run up a lot, with the expectation that vaccinations and time are going to get rid of the Covid issue, said Michael Hiley, head of over-the-counter energy trading at New York-based LPS Futures. “We’ve had the move, now we have to wait for the actual event to happen.”Brent’s prompt timespread was as much as 27 cents a barrel in backwardation -- where near-dated contracts are more expensive than later-dated ones -- compared with a 7-cent contango at the start of the month.About 1.7 billion trips are expected across China over the Lunar New Year period, down 40% from 2019, although 15% higher than last year. The travel rush, which starts on Jan. 28 this year, runs for 40 days and is normally the biggest mass movement of people around the globe as hundred of millions of Chinese jump on planes, trains and automobiles to see their extended families.In the U.S., analysts expect crude inventories rose last week, according to a Bloomberg survey. The industry-funded American Petroleum Institute will report its figures later Tuesday ahead of a U.S. government tally on Wednesday.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.